References
1. Tebbutt N, Pedersen MW and Johns TG. Targeting the ERBB family in
cancer: couples therapy. Nature reviews Cancer . 2013; 13: 663-73.
2. Thorpe LM, Yuzugullu H and Zhao JJ. PI3K in cancer: divergent roles
of isoforms, modes of activation and therapeutic targeting. Nature
reviews Cancer . 2015; 15: 7-24.
3. Dornan GL and Burke JE. Molecular Mechanisms of Human Disease
Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA
Phosphoinositide 3-Kinases. Frontiers in immunology . 2018; 9:
575.
4. Cheung LW and Mills GB. Targeting therapeutic liabilities engendered
by PIK3R1 mutations for cancer treatment. Pharmacogenomics . 2016;
17: 297-307.
5. Comprehensive molecular portraits of human breast tumours.Nature . 2012; 490: 61-70.
6. Chen L, Yang L, Yao L, et al. Characterization of PIK3CA and PIK3R1
somatic mutations in Chinese breast cancer patients. Nat Commun .
2018; 9: 1357.
7. Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell
lung cancer: comparison with original RECIST and impact on assessment of
tumor response to targeted therapy. AJR American journal of
roentgenology . 2010; 195: W221-8.
8. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and
PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for
regulation of PTEN protein stability. Cancer Discov . 2011; 1:
170-85.
9. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M and Bell DW. PIK3R1
(p85alpha) is somatically mutated at high frequency in primary
endometrial cancer. Cancer Res . 2011; 71: 4061-7.
10. Quayle SN, Lee JY, Cheung LW, et al. Somatic mutations of PIK3R1
promote gliomagenesis. PloS one . 2012; 7: e49466.
11. Cheung LW, Yu S, Zhang D, et al. Naturally occurring neomorphic
PIK3R1 mutations activate the MAPK pathway, dictating therapeutic
response to MAPK pathway inhibitors. Cancer cell . 2014; 26:
479-94.
12. Thorpe LM, Spangle JM, Ohlson CE, et al. PI3K-p110alpha mediates the
oncogenic activity induced by loss of the novel tumor suppressor
PI3K-p85alpha. Proc Natl Acad Sci U S A . 2017; 114: 7095-100.